About InDevR
InDevR is a company based in Boulder (United States) founded in 2003 by Laura Kuck. InDevR has raised $16 million across 15 funding rounds from investors including HHS, BioMerieux and National Dance Institute. InDevR offers products and services including VaxArray Platform, 5’CapQ Assay, and OmniFlu HA/NA 96. InDevR operates in a competitive market with competitors including Inflammatix, Agendia, Souzhou Ribo Life Science, GenomeDx Biosciences and Affymetrix, among others.
- Headquarter Boulder, United States
- Founders Laura Kuck
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Indevr, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16 M (USD)
in 15 rounds
-
Latest Funding Round
$9 M (USD), Series B
Jan 17, 2023
-
Investors
HHS
& 3 more
-
Employee Count
Not available
-
Acquired by
(Feb 06, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of InDevR
InDevR offers a comprehensive portfolio of products and services, including VaxArray Platform, 5’CapQ Assay, and OmniFlu HA/NA 96.
Multiplexed platform for vaccine antigen testing and quantification
Assay for measuring mRNA integrity in vaccine formulations
Kit for rapid influenza antigen detection and analysis
People of InDevR
Unlock access to complete
Funding Insights of InDevR
InDevR has successfully raised a total of $16M across 15 strategic funding rounds. The most recent funding activity was a Series B round of $9 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in InDevR
InDevR has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, BioMerieux and National Dance Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is deployed for global health technology innovations.
|
Locked | Locked | Locked | |
|
Developer of diagnostics devices for multiple health purposes
|
Locked | Locked | Locked | |
|
Center of education providing teacher training courses
|
Locked | Locked | Locked |
Investor details for InDevR
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by InDevR
Investment portfolio details for InDevR
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - InDevR
Detailed financials for InDevR
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Indevr Comparisons
Peer comparison for InDevR
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of InDevR
InDevR operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, Agendia, Souzhou Ribo Life Science, GenomeDx Biosciences and Affymetrix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of diagnostic solutions for systemic infections
|
|
| Locked | Locked | Locked |
Genomic diagnostic products for cancer treatment are provided.
|
|
| Locked | Locked | Locked |
Nucleic acid drugs are developed via RNA interference technology.
|
|
| Locked | Locked | Locked |
Genomic tests for urologic cancers are developed and commercialized.
|
|
| Locked | Locked | Locked |
Provider of technologies for multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level
|
|
| Locked | Locked | Locked |
Next-generation sequencing is provided for microbiology testing applications.
|
Detailed competitors of InDevR
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Indevr
Complete news archive for InDevR
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InDevR
InDevR was founded in 2003 and raised its 1st funding round 2 years after it was founded.
InDevR is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
InDevR is a funded company, having raised a total of $16M across 15 funding rounds to date.
Manufacturer of biotherapeutics, vaccines and diagnostic products. The company provides progressive analytical technologies that enhance and accelerate vaccine characterization and production. It also develops next-generation diagnostic products that will enable unprecedented tracking of seasonal and emerging influenza viruses around the globe. It offers a range of other microarray-related products. It provides the Cypher One product for automated hemagglutination analysis and the VaxArray Influenza potency assay for rapid quantification of hemagglutinin protein and many RD tools.
InDevR's top competitors include Inflammatix, Agendia and Souzhou Ribo Life Science.
InDevR offers VaxArray Platform, 5’CapQ Assay, and OmniFlu HA/NA 96.
InDevR has 4 investors. Key investors include HHS, BioMerieux, National Dance Institute, and Adjuvant Capital.